Acasti Pharma Gross Margin 2014-2024 | GRCE
Current and historical gross margin for Acasti Pharma (GRCE) over the last 10 years. The current gross profit margin for Acasti Pharma as of June 30, 2024 is %.
| Acasti Pharma Gross Margin Historical Data |
| Date |
TTM Revenue |
TTM Gross Profit |
Gross Margin |
| 2016-11-30 |
$0.00B |
0 |
nan% |
| 2016-05-31 |
$0.00B |
0 |
nan% |
| 2016-03-31 |
$0.00B |
0 |
nan% |
| 2015-12-31 |
$0.00B |
0 |
nan% |
| 2015-09-30 |
$0.00B |
0 |
nan% |
| 2015-06-30 |
$0.00B |
0 |
nan% |
| 2015-03-31 |
$0.00B |
0 |
nan% |
| 2014-12-31 |
$0.00B |
0 |
nan% |
| 2014-06-30 |
$0.00B |
0 |
nan% |
| 2014-03-31 |
$0.00B |
0 |
nan% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-GENERIC DRG |
$0.033B |
$0.000B |
|
Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R) is a medical food and currently Acasti's only commercialized product. Acasti Pharma Inc. is headquartered in Laval, Canada.
|
